Stockscreener 앱 받기
1.30
4.00%
0.05
시간 외 거래:
1.30
전일 마감가:
$1.25
열려 있는:
$1.25
하루 거래량:
687.33K
Relative Volume:
0.53
시가총액:
$221.47M
수익:
$4.71M
순이익/손실:
$-58.01M
주가수익비율:
-1.5788
EPS:
-0.8234
순현금흐름:
$-46.68M
1주 성능:
+1.56%
1개월 성능:
+4.00%
6개월 성능:
+4.00%
1년 성능:
+7.44%
1일 변동 폭
$1.232
$1.33
1주일 범위
$1.21
$1.4444
52주 변동 폭
$0.9495
$1.70
Lucid Diagnostics Inc Stock (LUCD) Company Profile
명칭
Lucid Diagnostics Inc
전화
212 949 4319
주소
360 MADISON AVENUE, NEW YORK
Compare LUCD vs ABT, SYK, MDT, BSX, EW
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
LUCD
Lucid Diagnostics Inc
|
1.30 | 212.95M | 4.71M | -58.01M | -46.68M | -0.8234 |
ABT
Abbott Laboratories
|
96.00 | 168.22B | 45.13B | 6.28B | 7.40B | 3.5895 |
SYK
Stryker Corp
|
338.34 | 131.49B | 25.12B | 3.25B | 4.28B | 8.3984 |
MDT
Medtronic Plc
|
85.00 | 110.66B | 35.48B | 4.64B | 5.41B | 3.582 |
BSX
Boston Scientific Corp
|
60.99 | 95.46B | 20.08B | 2.89B | 3.66B | 1.9391 |
EW
Edwards Lifesciences Corp
|
81.44 | 46.69B | 6.07B | 1.06B | 1.34B | 1.8063 |
Lucid Diagnostics Inc Stock (LUCD) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2021-12-27 | 개시 | Ascendiant Capital Markets | Buy |
| 2021-11-08 | 개시 | BTIG Research | Buy |
| 2021-11-08 | 개시 | Cantor Fitzgerald | Overweight |
| 2021-11-08 | 개시 | Needham | Buy |
Lucid Diagnostics Inc 주식(LUCD)의 최신 뉴스
Lucid Diagnostics (NASDAQ: LUCD) seeks 100M-share authorization increase - Stock Titan
Needham Reiterates Lucid Diagnostics (LUCD) Buy Recommendation - MSN
Lucid Diagnostics Inc. (NASDAQ:LUCD) Receives Average Recommendation of "Moderate Buy" from Analysts - MarketBeat
Needham Maintains Lucid Diagnostics(LUCD.US) With Buy Rating, Maintains Target Price $3 - 富途牛牛
Lucid Diagnostics Outperforms Pressure BioSciences in Key Metrics - National Today
Lucid Diagnostics (LUCD) CMO holds 650K shares including restricted stock - Stock Titan
Layoff Watch: Whats the MACD signal for Lucid Diagnostics Inc2026 Analyst Calls & Long Hold Capital Preservation Plans - baoquankhu1.vn
Lucid Diagnostics to Hold a Business Update Conference Call and Webcast on August 13, 2025 - Quantisnow
Fed Meeting: Is Lucid Diagnostics Inc stock forming a cup and handle2026 PreEarnings & Community Consensus Picks - baoquankhu1.vn
Dividend Watch: Can Lucid Diagnostics Inc be recession proofTrade Exit Report & Precise Swing Trade Alerts - baoquankhu1.vn
Ascendiant Maintains Lucid Diagnostics(LUCD.US) With Buy Rating, Raises Target Price to $9 - Moomoo
Breakout Move: What is the next catalyst for Lucid Diagnostics Inc2026 Performance Recap & Daily Profit Maximizing Tips - baoquankhu1.vn
Lucid Diagnostics to Participate in Needham Healthcare Conference - National Today
Lucid Diagnostics to Participate in Fireside Chat at the 25th Annual Needham Virtual Healthcare Conference - Bitget
Lucid Diagnostics to Participate in Fireside Chat at Healthcare Conference - National Today
Lucid Diagnostics CEO to Participate in Healthcare Conference - Intellectia AI
Lucid Diagnostics Inc. $LUCD Shares Purchased by Aberdeen Group plc - MarketBeat
Lucid CEO to speak at Needham healthcare conference on April 16 - Stock Titan
Lucid Diagnostics Inc. (NASDAQ:LUCD) Q3 2025 Earnings Call Transcript - MSN
Q3 2025 PAVmed Inc Earnings Call Transcript - GuruFocus
Aug Action: Whats the MACD signal for Lucid Diagnostics Inc2026 Earnings Surprises & Fast Gaining Stock Strategy Reports - baoquankhu1.vn
LUCD PE Ratio & Valuation, Is LUCD Overvalued - Intellectia AI
Lucid Diagnostics Inc. (LUCD) stock price, news, quote and history - Yahoo Finance UK
PAVmed Appoints New Executive to Drive Medical Device Development - Intellectia AI
PAVmed appoints Joseph Virgilio as medical device chief By Investing.com - Investing.com Canada
PAVmed Appoints Joseph Virgilio to Lead Relaunched Medical Device Portfolio - ChartMill
Duke-licensed esophageal imaging joins PAVmed device relaunch - Stock Titan
Lucid Diagnostics Inc. (NASDAQ:LUCD) Short Interest Update - MarketBeat
Dow Update: Can Lucid Diagnostics Inc be recession proof2026 Key Highlights & Accurate Intraday Trade Tips - baoquankhu1.vn
Lucid Diagnostics’ Earnings Call: Momentum Amid Cash Strain - The Globe and Mail
LUCD: BTIG Reiterates Buy Rating with $2.50 Price Target | LUCD Stock News - GuruFocus
Profit Review: Whats the MACD signal for Lucid Diagnostics Inc2026 Trends & Scalable Portfolio Growth Ideas - baoquankhu1.vn
PAVmed Reports 2025 Financial Results, Strengthens Capital Structure, and Expands Medical Device Portfolio Under New Leadership - Minichart
BTIG reiterates Lucid Diagnostics stock rating on Q4 beat By Investing.com - Investing.com South Africa
Lucid Diagnostics (NASDAQ:LUCD) Earns Buy Rating from BTIG Research - MarketBeat
PAVmed (NASDAQ: PAVM) overhauls capital structure and reports 2025 results - Stock Titan
Lucid Diagnostics (LUCD) Earnings Transcript - AOL.com
PAVmed Provides Business Update and Reports Fourth Quarter and Full Year 2025 Financial Results - MarketScreener
BTIG reiterates Lucid Diagnostics stock rating on Q4 beat - Investing.com
Lucid Diagnostics Inc. (LUCD) reports Q4 loss, beats revenue estimates - MSN
Lucid Diagnostics non-GAAP adjusted loss hits USD 12.6M in Q4 2025 - Medical Buyer
Lucid Diagnostics (NASDAQ:LUCD) Rating Increased to Hold at Wall Street Zen - MarketBeat
Valuation Update: What is the long term forecast for Lucid Diagnostics Inc stockQuarterly Trade Review & Stepwise Trade Execution Plans - baoquankhu1.vn
PAVmed (PAVM) outlines going concern risk, Nasdaq compliance and growth plans - stocktitan.net
Lucid Diagnostics (NASDAQ:LUCD) Issues Earnings Results, Misses Estimates By $0.03 EPS - MarketBeat
Lucid Diagnostics Inc. (NASDAQ:LUCD) Q4 2025 Earnings Call Transcript - Insider Monkey
[EFFECT] Lucid Diagnostics Inc. SEC Filing - Stock Titan
Lucid Diagnostics Provides Business Update and Reports Fourth Quarter and Full Year 2025 Financial Results - StreetInsider
Lucid Diagnostics Inc. 2025 Q4ResultsEarnings Call Presentation (NASDAQ:LUCD) 2026-03-27 - Seeking Alpha
Canaccord Genuity Sticks to Its Buy Rating for Lucid Diagnostics (LUCD) - The Globe and Mail
Lucid Diagnostics reports Q4 revenue of $1.5M, VA contract By Investing.com - Investing.com South Africa
Lucid Diagnostics Inc (LUCD) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.74%
1.72%
자본화:
|
볼륨(24시간):